Clinical Trials List
2017-07-26 - 2020-06-30
Phase III
Terminated5
ICD-10C50
Malignant neoplasm of breast
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 邱仁輝 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- Yi-Fang Tsai Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- 林燕淑 Division of General Surgery
- 金光亮 Division of General Surgery
- 林永慧 Division of Radiology
The Actual Total Number of Participants Enrolled
3 Terminated
Audit
None
Co-Principal Investigator
- 張端瑩 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
- MING-YANG WANG Division of General Surgery
- 林季宏 Division of Hematology & Oncology
- 蔡立威 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- 林柏翰 Division of General Internal Medicine
- 郭文宏 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- 黃文聰 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Shau-Hsuan Li Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 褚乃銘 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
858 participants
